RS50262B2 - Farmaceutska kombinacija etinilestradiola i drospirenona za primenu kao kontraceptivnog sredstva - Google Patents

Farmaceutska kombinacija etinilestradiola i drospirenona za primenu kao kontraceptivnog sredstva

Info

Publication number
RS50262B2
RS50262B2 RS14502A RSP20020145A RS50262B2 RS 50262 B2 RS50262 B2 RS 50262B2 RS 14502 A RS14502 A RS 14502A RS P20020145 A RSP20020145 A RS P20020145A RS 50262 B2 RS50262 B2 RS 50262B2
Authority
RS
Serbia
Prior art keywords
drospirenone
active agent
ethinylestradiol
administration
composition
Prior art date
Application number
RS14502A
Other languages
English (en)
Inventor
Wolfgang Heil
Jürgen HILMAN
Ralph Lipp
Renate Heithecker
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26153359&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS50262(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of RS50262B2 publication Critical patent/RS50262B2/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Farmaceutska kompozicija koja sadrži, kao prvo aktivno sredstvo. 6β.7β; 15β,16β-dimetilen-3-okso-17α-pregn-4-en-21,17-karbolakton (drospirenon) u količini koja odgovara jednoj dnevnoj dozi, nakom davanja kompozicije, od oko 2 mg do oko 4 mg, i, kao drugo aktivno sredstvo, 17α-etinilestradiol (etinilestra-diol) u količini koja odgovara dnevnoj dozi od oko 0,01 mg do oko 0,05 mg, zajedno sa jednim ili više farmaceutski prihvatljivih nosača ili neutralnih dodataka. Kod jednog posebnog izvođenja, kompozicija se sastoji od više odvojeno pakovanih i pojedinačno odvojivih dnevnih doznih jedinica postavljenih u jednu jedinicu pakovanja i namenjenih za oralno davanje u trajanju od najmanje 21 dan zaredom, pri čemu pomenute dnevne dozne jedinice sadrže svaka jednu kombinaciju drospirenona i etinilestradiola. Kompozicija može dalje sadržati 7 ili manje dnevnih doznih jedinica koje ne sadrže nikakvo aktivno sredstvo ili sadrže sam etinilestradiol.

Claims (2)

PATENTNI ZAHTEVI
1. Tableta, što sadrži, kao prvo aktivno sredstvo drospirenon u količini koja odgovara dnevnoj dozi, pri davanju tablete, od 3 mg, i kao drugo aktivno sredstvo, etinilestradiol u količini koja odgovara dnevnoj dozi od oko 0,015 mg do 0,03 mg, zajedno sa jednim ili više farmaceutski prihvatljivih nosača ili inertnih punilaca naznačena time što se bar 70% navedenog drospirenona rastvori iz navedene tablete koja sadrži 3 mg drospirenona za 30 minuta, kako je to utvrđeno putem USP XXIII Paddle Method II upotrebom 900 ml vode na 37°C kao medijuma rastvaranja i pri brzini mešanja od 50 obrtaja u minuti.
2. Tableta prema zahtevu 1, naznačena time, što je etinilestradiol u mikronizovanom obliku.
RS14502A 1999-08-31 2000-08-31 Farmaceutska kombinacija etinilestradiola i drospirenona za primenu kao kontraceptivnog sredstva RS50262B2 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38627499A 1999-08-31 1999-08-31
EP99202826 1999-08-31
PCT/IB2000/001213 WO2001015701A1 (en) 1999-08-31 2000-08-31 Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive

Publications (1)

Publication Number Publication Date
RS50262B2 true RS50262B2 (sr) 2018-10-31

Family

ID=26153359

Family Applications (3)

Application Number Title Priority Date Filing Date
RS14502A RS50262B2 (sr) 1999-08-31 2000-08-31 Farmaceutska kombinacija etinilestradiola i drospirenona za primenu kao kontraceptivnog sredstva
YU14502A RS50262B (sr) 1999-08-31 2000-08-31 Farmaceutska kombinacija etinilestradiola i drospirenona za primenu kao kontraceptivnog sredstva
RSP-2009/0134A RS20090134A (sr) 1999-08-31 2000-08-31 Farmaceutska kombinacija etinilestradiola i drospirenona za primenu kao kontraceptivnog sredstva

Family Applications After (2)

Application Number Title Priority Date Filing Date
YU14502A RS50262B (sr) 1999-08-31 2000-08-31 Farmaceutska kombinacija etinilestradiola i drospirenona za primenu kao kontraceptivnog sredstva
RSP-2009/0134A RS20090134A (sr) 1999-08-31 2000-08-31 Farmaceutska kombinacija etinilestradiola i drospirenona za primenu kao kontraceptivnog sredstva

Country Status (26)

Country Link
EP (4) EP2044941A1 (sr)
JP (2) JP4354667B2 (sr)
KR (2) KR101019361B1 (sr)
AT (3) ATE254464T1 (sr)
AU (4) AU780330B2 (sr)
BG (1) BG66114B1 (sr)
BR (1) BR0014159A (sr)
CY (3) CY1108990T1 (sr)
CZ (1) CZ300514B6 (sr)
DE (5) DE60042089D1 (sr)
DK (3) DK1214076T3 (sr)
EE (1) EE05128B1 (sr)
ES (3) ES2211580T3 (sr)
HK (1) HK1047247B (sr)
HR (1) HRP20070188B1 (sr)
HU (1) HU227207B1 (sr)
IL (1) IL148339A0 (sr)
ME (2) ME00329B (sr)
NO (1) NO326860B1 (sr)
NZ (1) NZ517845A (sr)
PL (1) PL199028B1 (sr)
PT (3) PT1380301E (sr)
RS (3) RS50262B2 (sr)
SI (3) SI1214076T1 (sr)
TW (1) TWI276436B (sr)
WO (1) WO2001015701A1 (sr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS50262B2 (sr) * 1999-08-31 2018-10-31 Bayer Pharma AG Farmaceutska kombinacija etinilestradiola i drospirenona za primenu kao kontraceptivnog sredstva
KR100913910B1 (ko) * 2000-01-18 2009-08-26 바이엘 쉐링 파마 악티엔게젤샤프트 호르몬 보충 요법용 드로스피렌온
JO2334B1 (en) * 2000-01-18 2006-06-28 باير شيرنغ فارما اكتنجيسيلشافت Drospirenone for hormone replacement therapy
WO2002049674A1 (en) * 2000-12-20 2002-06-27 Schering Aktiengesellschaft Cyclodextrin-drospirenone inclusion complexes
EP1216713A1 (en) 2000-12-20 2002-06-26 Schering Aktiengesellschaft Compositions of estrogen-cyclodextrin complexes
WO2003090755A1 (en) * 2002-04-26 2003-11-06 Schering Aktiengesellschaft Treatment of hypertension in women receiving hormone replacement therapy
US7786101B2 (en) 2002-11-05 2010-08-31 Bayer Schering Pharma Ag Cardiovascular protection using anti-aldosteronic progestins
MY142989A (en) 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
DE602005014227D1 (de) * 2004-03-10 2009-06-10 Bayer Schering Pharma Ag Zusammensetzungen aus drospirenon in molekularer dispersion
MY151322A (en) 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
EP1625849A1 (en) * 2004-08-09 2006-02-15 Liconsa, Liberacion Controlada de Sustancias Activas, S.A. Pharmaceutical composition comprising drospirenone and ethynylestradiol
US8216611B2 (en) * 2005-03-30 2012-07-10 Mylan Pharmaceuticals Ulc Combined-step process for pharmaceutical compositions
UY29527A1 (es) 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.
EP1767194A1 (de) * 2005-06-09 2007-03-28 Helm AG Verfahren zur Herstellung von Adsorbaten des Drospirenons
CN101489563A (zh) * 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
US8617597B2 (en) 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
EP1900359A1 (en) * 2006-09-16 2008-03-19 KAIROSmed GmbH Oral modified release formulations containing drospirenon and 8-prenylnaringenin for use in female contraception
JP2010503632A (ja) * 2006-09-16 2010-02-04 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 経口改良放出製剤
PE20090805A1 (es) * 2007-04-05 2009-07-25 Bayer Schering Pharma Ag COMBINACION DE DROSPIRENONA Y 17ß-ESTRADIOL COMO CONTRACEPTIVO ORAL
HUP0700826A3 (en) 2007-12-20 2010-03-29 Richter Gedeon Nyrt Coated tablet containing drospirenone and process for producing the same
WO2009112232A2 (en) * 2008-03-10 2009-09-17 Vladimir Hanes New drospirenone/17beta-estradiol regimen, pharmaceutical combination product and kit for performing this regimen
TW200942242A (en) * 2008-03-10 2009-10-16 Rolf Schurmann New drospirenone/17β-estradiol regimen, pharmaceutical combination product and kit for performing this regimen
WO2009138224A1 (en) * 2008-05-14 2009-11-19 Helm Ag Pharmaceutical composition comprising drospirenone
DE102008037025C5 (de) 2008-08-08 2016-07-07 Jesalis Pharma Gmbh Verfahren zur Herstellung kristalliner Wirkstoff-Mikropartikel bzw. einer Wirkstoffpartikel-Festkörperform
EP2398461A1 (en) * 2009-02-18 2011-12-28 Bayer Pharma Aktiengesellschaft Formulation comprising drospirenone for subcutaneous or intramuscular administration
UY32836A (es) 2009-08-12 2011-03-31 Bayer Schering Pharma Ag Partículas estabilizadas que comprenden 5-metil-(6s)-tetrahidrofolato
KR20130097073A (ko) * 2010-04-15 2013-09-02 바이엘 인텔렉쳐 프로퍼티 게엠베하 초저-용량의 ｈｒｔ용 고체 경구 투여 형태
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
IT202100008834A1 (it) 2021-04-08 2022-10-08 Ind Chimica Srl Processo per la preparazione di drospirenone come polvere fine tramite duplice cambio di forma cristallina
WO2023152658A1 (en) 2022-02-10 2023-08-17 Lupin Limited Slow release drospirenone tablet composition
US20250186337A1 (en) * 2022-03-01 2025-06-12 Chemo Research, S.L. Chewable oral contraceptive

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2652761C2 (de) 1976-11-16 1985-11-21 Schering AG, 1000 Berlin und 4709 Bergkamen 15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE3051167C3 (de) * 1979-01-24 1994-11-24 Minnesota Mining & Mfg Fluorierte Alkohole
DE3051166C2 (en) 1980-06-11 1990-10-18 Schering Ag, 1000 Berlin Und 4709 Bergkamen, De Compsns. for contraception or treatment of gynaecological disorders
DE3347125A1 (de) 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen Mehrstufenkombinationspraeparat und seine verwendung zur oralen kontrazeption
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
EP0209403B1 (en) * 1985-07-15 1991-10-23 Research Development Corporation of Japan Process for preparing ultrafine particles of organic compounds
DE3916112A1 (de) 1989-05-16 1990-11-22 Schering Ag Dihydrospirorenon als antiandrogen
DE4227989A1 (de) 1992-08-21 1994-06-09 Schering Ag Mittel zur transdermalen Applikation enthaltend 3-Keto-desogestrel
DK95093D0 (da) * 1993-08-20 1993-08-20 Novo Nordisk As Farmaceutisk formulering indeholdende et hormon
ZA939566B (en) * 1993-12-21 1994-08-11 Applied Analytical Ind Inc Method for dry blend compression od medicaments.
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
DE4411585A1 (de) * 1994-03-30 1995-10-05 Schering Ag Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption
DE4429374C1 (de) * 1994-08-12 1996-02-01 Jenapharm Gmbh Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente
ATE236639T1 (de) * 1994-09-22 2003-04-15 Akzo Nobel Nv Verfahren zur herstellung von dosierungsformen durch feuchtgranulierung
DE19525017A1 (de) * 1995-06-28 1997-01-02 Schering Ag Pharmazeutisches Kombinatonspräparat, Kit und Methode zur hormonalen Kontrazeption
US5922349A (en) * 1995-09-28 1999-07-13 Schering Aktiengesellschaft Hormone replacement therapy method and hormone dispenser
DE19540253C2 (de) * 1995-10-28 1998-06-04 Jenapharm Gmbh Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene
AU3888697A (en) * 1996-07-26 1998-02-20 American Home Products Corporation Progestin/estrogen oral contraceptive
NZ333750A (en) * 1996-07-26 2000-09-29 American Home Prod Monophasic contraceptive method and kit comprising a combination of a progestin and estrogen
ATE278406T1 (de) * 1996-07-26 2004-10-15 Wyeth Corp Orales contrazeptivum
DE19633685C1 (de) 1996-08-12 1997-10-09 Schering Ag Verfahren zur Herstellung von Drospirenon (6beta,7beta;15 beta,16beta-Dimethyl-en-3-oxo-17alpha-pregn-4-en-21,17-carbolacton, DRSP) sowie 7alpha-(3-Hydroxy-1-propyl)-6beta,7beta;15beta, 16beta-dimethylen-5beta-androstan-3beta,5,17beta-triol (ZK 92836) und 6beta,7beta;15beta,16beta-dimethylen-5beta-hydroxy-3-oxo-17alpha-androstan-21,17-carbolacton (90965) als Zwischenprodukte des Verfahrens
DE19651000A1 (de) 1996-12-01 1998-06-04 Schering Ag Oxyiminopregnancarbolactone
RS50262B2 (sr) * 1999-08-31 2018-10-31 Bayer Pharma AG Farmaceutska kombinacija etinilestradiola i drospirenona za primenu kao kontraceptivnog sredstva
KR100913910B1 (ko) * 2000-01-18 2009-08-26 바이엘 쉐링 파마 악티엔게젤샤프트 호르몬 보충 요법용 드로스피렌온

Also Published As

Publication number Publication date
KR101019361B1 (ko) 2011-03-07
KR20070067248A (ko) 2007-06-27
JP2009143959A (ja) 2009-07-02
ATE429231T1 (de) 2009-05-15
DE60041421D1 (de) 2009-03-05
IL148339A0 (en) 2002-09-12
NZ517845A (en) 2004-12-24
NO20020801D0 (no) 2002-02-19
EP1598069B1 (en) 2009-04-22
EE05128B1 (et) 2009-02-16
HRP20070188B1 (hr) 2015-06-19
DE122009000006I1 (de) 2009-05-07
PT1598069E (pt) 2009-07-20
KR20020040798A (ko) 2002-05-30
MEP36008A (hr) 2011-02-10
RS50262B (sr) 2009-07-15
EP1380301B1 (en) 2009-01-14
DE122009000007I2 (de) 2011-07-21
SI1214076T1 (en) 2004-06-30
HU227207B1 (en) 2010-11-29
EP1598069A3 (en) 2006-04-05
DE60042089D1 (de) 2009-06-04
JP4354667B2 (ja) 2009-10-28
BG66114B1 (bg) 2011-05-31
DE60006692T2 (de) 2004-09-23
HUP0202500A3 (en) 2004-04-28
DE60006692D1 (de) 2003-12-24
DK1214076T3 (da) 2004-02-23
AU6589500A (en) 2001-03-26
RS20090134A (sr) 2009-11-10
HK1047247B (en) 2004-07-23
EP1214076A1 (en) 2002-06-19
BR0014159A (pt) 2002-05-07
EP1380301A1 (en) 2004-01-14
PT1214076E (pt) 2004-04-30
WO2001015701A1 (en) 2001-03-08
ES2319750T3 (es) 2009-05-12
EE200200110A (et) 2003-06-16
AU2009200247B2 (en) 2010-07-01
CY2009015I1 (el) 2014-02-12
CZ2002615A3 (cs) 2002-08-14
AU2005202046B9 (en) 2008-12-11
HK1061968A1 (en) 2004-10-15
ATE254464T1 (de) 2003-12-15
HK1047247A1 (en) 2003-02-14
AU2005202046A1 (en) 2005-06-09
HK1082432A1 (en) 2006-06-09
SI1598069T1 (sl) 2009-10-31
PL354406A1 (pl) 2004-01-12
DE122009000007I1 (de) 2009-05-07
HUP0202500A2 (en) 2002-10-28
PT1380301E (pt) 2009-03-30
AU780330B2 (en) 2005-03-17
CY1109252T1 (el) 2014-07-02
AU2009200247A1 (en) 2009-02-19
EP1214076B1 (en) 2003-11-19
EP2044941A1 (en) 2009-04-08
ME00329B (me) 2011-05-10
DK1598069T3 (da) 2009-07-06
EP1598069A2 (en) 2005-11-23
DK1380301T3 (da) 2009-04-20
CY2009015I2 (el) 2014-02-12
HRP20070188A2 (en) 2007-07-31
AU2005202046B2 (en) 2008-11-20
KR100857344B1 (ko) 2008-09-05
CY1108990T1 (el) 2014-02-12
CZ300514B6 (cs) 2009-06-03
AU2010226924A1 (en) 2010-10-28
PL199028B1 (pl) 2008-08-29
DE122009000006I2 (de) 2012-03-22
YU14502A (sh) 2006-01-16
TWI276436B (en) 2007-03-21
ES2211580T3 (es) 2004-07-16
SI1380301T1 (sl) 2009-06-30
NO326860B1 (no) 2009-03-02
ATE420648T1 (de) 2009-01-15
ES2325589T3 (es) 2009-09-09
NO20020801L (no) 2002-04-26
JP2003508441A (ja) 2003-03-04

Similar Documents

Publication Publication Date Title
RS50262B2 (sr) Farmaceutska kombinacija etinilestradiola i drospirenona za primenu kao kontraceptivnog sredstva
ES2558030T3 (es) Método anticonceptivo oral multifásico de ciclo prolongado
FI98984C (fi) Ehkäisyvalmiste, joka sisältää ainoastaan progestogeenia
KR900701277A (ko) 피임 시스템 및 방법
NO179311B (no) Flerfasekombinasjons- og kontraseptiv pakke
WO2008031631A2 (en) Oral modified release formulations
AU667729B2 (en) Minimizing progestin associated breakthrough bleeding
KR19990076685A (ko) 게스타겐 및 에스트로겐의 배합을 포함하는 암컷 포유동물용 피임 방법 및 키트
JP2010539153A5 (sr)
NO327588B1 (no) Farmasoytisk sammensetning og preparat omfattende etinylostradiol og drospirenon for anvendelse som antikonsepsjonsmiddel
RU2002107987A (ru) Фармацевтическая комбинация этинилэстрадиола и дроспиренона для использования в качестве контрацептива
HRP20090256T1 (en) Use of estradiolvalerate and dienogest for oral treatment of dysfunctional uterine bleeding in a contraceptive method
HUP0100542A2 (hu) Progesztogént és anti-progesztogént tartalmazó kit, eljárás előállítására és a vegyületek alkalmazása fogamzásgátló szer előállítására
RU2000115313A (ru) Схемы приема гестаген-анти-гестагена
KR20150085512A (ko) 필요시 피임을 위한 레보노르게스트렐 및 cox 억제제 함유 제약 조성물의 용도 및 적용 요법
PT1148882E (pt) Utilização de um agente redutor do teor de homocisteína no plasma para redução do risco de efeitos secundários tromboembólicos induzidos por hormonas do tipo dos gestagénios
JPH08508502A (ja) 骨粗しょう症の治療方法および治療用組成物
AR025443A1 (es) Una composicion farmaceutica para ser usada como anticonceptivo.
MXPA00004610A (en) Progestogen-antiprogestogen regimens